And in fact, the congressional investigation cited one case where four out of five members of the panel were working for Merck when they approved a vaccine for Merck. And One of the people on that [vaccine recommendation] panel who voted had a patent on that vaccine, which he then sold for $186 million. So we wanted to make sure there are people on that panel for the first time in history that don't have conflicts of interest that are not making money by voting themselves rich. (01:34–01:42)
CLAIM
Asserts that a panel member profited from a vaccine patent after approval.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
